SIM 0811
Alternative Names: SIM-0811Latest Information Update: 16 Feb 2026
At a glance
- Originator Jiangsu Simcere Pharmaceutical
- Class Anti-ischaemics; Small molecules; Vascular disorder therapies
- Mechanism of Action Epoxide hydrolase inhibitors; Plasminogen activators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Ischaemic stroke; Myocardial infarction
Most Recent Events
- 02 Feb 2026 Phase-I clinical trials in Ischaemic stroke (In volunteers) in China (IV) (Simcere Pharmaceutical pipeline, February 2026) (NCT07345364)
- 02 Feb 2026 Phase-I clinical trials in Myocardial infarction (In volunteers) in China (IV) (Simcere Pharmaceutical pipeline, February 2026) (NCT07345364)
- 28 Jan 2026 Preclinical trials in Ischaemic stroke in China (IV) (Jiangsu Simcere Pharmaceutical Pipeline, January 2026)